Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02155660 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,255
- Enrollment target
NCT02155660 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 2,255 participants.
The verdict
NCT02155660, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,255 participants
- Enrollment target
Study Summary
The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies.
Interventions
- DRUG Placebo
- DRUG Benralizumab Arm A
- DRUG Benralizumab Arm B
- DRUG Benralizumab Arm C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,255 participants |
| Start Date | 2014-06-25 |
| Est. Completion | 2018-04-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02155660
The ClinicalTrials.gov registry entry for NCT02155660 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,255 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02155660 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02155660 about?
NCT02155660 is a clinical study titled "Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History". The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies.
What is the current status of trial NCT02155660?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,255 participants. The study started on 2014-06-25. Estimated completion is 2018-04-09.
What interventions are being tested in trial NCT02155660?
The interventions under investigation include: Placebo (DRUG), Benralizumab Arm A (DRUG), Benralizumab Arm B (DRUG), Benralizumab Arm C (DRUG).
Who is sponsoring clinical trial NCT02155660?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.